Determination of Regulatory Review Period for Purposes of Patent Extension; KIMMTRAK

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for KIMMTRAK, a human biological product, following a patent extension application submitted to the US Patent and Trademark Office (USPTO).